



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support

31 Mar 2020 (#15)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or www.sun.ac.za/RDSfunding (current & archive).

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizelk@sun.ac.za

Important Notice

[NOT-AI-20-031](#) Notice of Special Interest (NOSI): Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) NIAID is issuing this Notice of Special Interest (NOSI) to highlight the need for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NIAID is particularly interested in projects focusing on viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against SARS-CoV-2/COVID-19. NIAID is therefore encouraging applications to address research objectives described in the notice. This notice applies to due dates on or after April 5, 2020 and subsequent receipt dates through April 5, 2021.

[NOT-AI-20-034](#) Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NIAID is issuing this Notice of Special Interest (NOSI) to highlight the need for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NIAID is particularly interested in projects focusing on viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against SARS-CoV-2/COVID-19. NIAID is therefore offering Competitive Revisions to active NIAID grants addressing research objectives.

[NOT-HS-20-008](#) Notice of Intent: New Funding Opportunity Announcement to Support Novel, High-Impact Studies Evaluating Health System and Healthcare Professional Responsiveness to COVID-19. AHRQ intends to publish a new funding opportunity announcement using the R01 mechanism to support novel, high-impact studies evaluating health system and healthcare professional responsiveness to COVID-19. This Notice is being provided to allow potential applicants sufficient time to develop responsive applications. The health systems research community should prepare to submit applications to AHRQ to fund critical research focused on evaluating topics such as innovations and challenges encountered in the rapid expansion of telemedicine in response to COVID-19, effects on quality, safety, and value of health system response to COVID-19, and the role of primary care practices and professionals during the COVID-19 epidemic. AHRQ is particularly interested in understanding how digital health innovations contributed to health system and healthcare professional innovation and challenges and solutions to meeting the needs of vulnerable populations including older adults, people living with multiple chronic conditions, rural communities, and uninsured and underinsured populations. AHRQ will encourage multimethod, rapid-cycle research with the ability to produce and disseminate findings as early as 6 months. AHRQ expects to invest up to \$5M in FY2020 funds to support this initiative and potentially more pending supplemental funding. AHRQ is working to publish the FOA in early May 2020 with submissions due in June 2020.

[NOT-TR-20-012](#) Notice of Special Interest (NOSI): Repurposing Existing Therapeutics to Address the 2019 Novel Coronavirus Disease (COVID-19). National Center for Advancing Translational Sciences (NCATS) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 novel coronavirus (SARS-CoV-2) and the disease it causes, i.e., "coronavirus disease 2019" (COVID-19). NCATS is particularly interested in projects that repurpose existing drugs or biologics (existing therapeutics) that have already begun or completed a Phase I clinical trial. Submit applications for this initiative using one of the following funding opportunity announcements (FOAs) or any reissues of these announcement through the expiration date of this notice:

Codes	FOA Title	Applicable Dates
UG3/UH3	PAR-17-465 : Bench Testing Therapeutic/Indication Paring Strategies	June 26, 2020
U34	PA-18-462 :Clinical Trial Planning: Therapeutic/Indication Pairing Strategies (U34) (Clinical Trial Not Allowed)	June 16, 2020 October 16, 2020
U01	PAR-18-332 : Clinic Testing Therapeutic/Indications Pairing Strategies (U01 Clinical Trial Required)	June 5, 2020 October 5, 2020

[NOT-HS-20-007](#) Notice of Intent: Revision Supplements to Existing AHRQ Grants and Cooperative Agreements to Address Health System Responsiveness to COVID-19 intends to publish a new funding notice allowing requests for urgent revision supplements to existing AHRQ grants and cooperative agreements to address health system responsiveness to COVID-19. AHRQ intends to allow grantees with active AHRQ research grants to submit requests for competitive revision supplements to address timely health system and healthcare professional response to COVID-19. Grant activity codes to be included or excluded from the funding notice will be specified in the announcement. It is expected that competitive revision supplement requests will capitalize on the expertise of grant personnel and the institutional environment to expand the specific aims of the on-going research to develop high-impact new knowledge concerning COVID-19. Competitive revision supplements will be limited in duration (perhaps 12 months). The amount of supplemental funds that may be requested will be limited, and will be specified in the funding notice. AHRQ expects to make at least \$2.5M available to fund meritorious revision supplements in FY2020. AHRQ plans to release the supplement announcement in April 2020 with an opening date in mid-May.

[NOT-DA-20-018](#) Notice of Special Interest (NOSI): Exploring the Roles of Biomolecular Condensates (BMCs) in Substance Use Disorder and/or HIV-related processes. The purpose of this Notice is to inform potential applicants to the National Institute on Drug Abuse (NIDA) of special interest in research examining the roles of biomolecular condensates (BMCs) or their regulators in processes relevant to substance use disorders (SUDs) and/or HIV infection, latency, or pathogenesis. BMCs and HIV. There is much we do not know about BMCs in HIV biology. For example, it has recently been shown that vesicular stomatitis virus (VSV) exploits a nuclear BMC for efficient replication of the VSV RNA genome, but it is not known if HIV uses a BMC for a similar purpose. Despite the emerging role for BMCs in establishing and regulating chromatin structure in the nucleus, little is known about the potential involvement of BMCs in HIV/SIV infection, the formation or maintenance of HIV latency or whether HIV latency could be strengthened or diminished by manipulation of nuclear BMCs. Dysregulation of BMC-related processes also could be involved in the etiology of HIV-associated Neurocognitive Disorder (HAND). This notice applies to due dates on or after June 5, 2019 and subsequent receipt dates through September 8, 2023.

[NOT-GM-20-025](#) Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on Coronavirus Disease 2019 (COVID-19) and the Causative Virus SARS-CoV-2. There is an urgent public health need to better understand SARS-CoV-2, particularly to improve the predictive quality of existing models of spread, diagnostics for measurement of transmission, susceptibility and recovery, and development of therapeutic interventions. NIGMS will accept the submission of applications for Competitive Revisions to active grants to address only the following research areas of interest: Incorporation of data related to SARS-CoV-2 into ongoing research efforts to develop predictive models for the spread of SARS-CoV-2 and other related infectious agents (all relevant grants). Applications in response to this NOSI must be submitted to [PA-18-935](#). Applications will be accepted on a rolling basis **from March 25, 2020 to February 5, 2021**. Research Strategy section of the application is limited to 6 pages. The award project period of the Competitive Revision must not exceed one year. Application budgets are limited to no more than the amount of the current parent award. The parent award must be active when the application is submitted.

[NOT-MH-20-019](#) Notice of Special Interest (NOSI): Strengthening the HIV Prevention Continuum. The National Institute of Mental Health is issuing this Notice to highlight interest in receiving grant applications focused on strengthening the HIV prevention continuum by understanding attendant challenges and advancing novel interventions. NIMH calls for research that will improve the scientific understanding of gaps and challenges in the HIV prevention continuum, as well as studies to develop and test interventions designed to strengthen the HIV prevention continuum and prevention outcomes.

[The National Library of Medicine expands access to coronavirus literature through PubMed Central.](#) The National Library of Medicine (NLM), part of the National Institutes of Health, is working on multiple fronts to aid in the COVID-19 response through new initiatives with the global publishing community and artificial intelligence researchers. NLM is expanding access to scientific papers on coronavirus for researchers, care providers, and the public, and for text-mining research. NLM has already made more than 10,000 full-text scholarly articles from PMC related to the coronavirus available through the [COVID-19 Open Research Dataset \(CORD-19\)](#)

[LitCovid](#) is a curated literature hub for tracking up-to-date scientific information about the 2019 novel Coronavirus. It is the most comprehensive resource on the subject, providing a central access to relevant articles in PubMed. The articles are updated daily and are further categorized by different research topics and geographic locations for improved access.

1. Innovations in HIV Prevention, Testing, Adherence and Retention to Optimize HIV Prevention and Care Continuum Outcomes (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PA-20-144](#)

Type: R01

Application Due Date: [Standard AIDS dates](#) .Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This FOA seeks innovative research to optimize HIV prevention and care which is aligned with NIMH Division of AIDS Research (DAR) priorities. Applications may include formative basic behavioral and social science to better understand a step or steps in the HIV prevention or care continuum, and/or the initial development and pilot testing of innovative intervention approaches, and intervention efficacy or effectiveness trials. Applicants are encouraged to read current Notices of Special Interests (NOSIs) from NIMH DAR for further information about the Division's research priorities. [PA-20-145](#) uses the R21 grant mechanism while this [PA-20-144](#) uses the R01 mechanism. High risk/high payoff projects that lack preliminary data or utilize existing data may be most appropriate for the R21 mechanism, while applications with preliminary data and/or including longitudinal analysis may be more appropriate for the R01 mechanism.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

2. Extracellular RNA carrier subclasses in processes relevant to Substance Use Disorders or HIV infection (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-20-147](#)

Type: R01

Application Due Date: AIDS dates January 7, 2021, May 7, 2021, January 7, 2022, May 7, 2022, January 7, 2023, May 7, 2023 .Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this FOA is to encourage research investigating the roles of extracellular RNA (exRNA) carrier subclasses in biological processes relevant to substance use disorders (SUDs) and/or HIV infection, latency, or pathogenesis in the CNS. Applicants may propose to investigate biological mechanisms involving exRNA carrier subclasses, or propose to develop improved technologies to investigate extracellular vesicles or other exRNA carriers.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

3. Long Acting Treatments for HIV and HIV-Associated Co-Infections (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-AI-20-024](#)

Type: R61/R33

Application Due Date: July 28, 2020. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity is to stimulate new and innovative multidisciplinary research in the area of long acting therapeutics for HIV and HIV-associated tuberculosis (TB) and viral hepatitis B and C. Applications are sought that lead to new effective therapies for administration once per month or less frequently as oral, injectable, implantable, or transdermal products.

Budget: NIAID intends to commit \$3.5M in FY 2021 to fund 3-5 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The total project period for an application submitted in response to this FOA is five years. Applicants may request up to three years of support for the R61 phase, and up to two years of support for the R33 phase.

4. Exploiting in vivo or in situ imaging approaches to understand HIV-relevant processes in the context of substance use disorders (Clinical Trials Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-DA-21-005](#)

Type: R61/R33

Application Due Date: July 14, 2020. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this initiative is to support projects that further develop or exploit advances using in situ or in vivo imaging or related technologies to investigate HIV/SIV infection, latent reservoirs, the pathogenic consequences of HIV/SIV infection, or the effects of substance use, substance use disorders (SUDs), or HIV or SUD therapies on these processes. Applicants may propose primate or human studies to investigate blood, lymphoid, or brain tissues.

Budget: NIDA intends to commit \$3 M in FY2021 to fund 5-8 awards. Applications may not request more than \$350k direct costs for any single year of the R61 phase or more than \$500k direct costs for any single year of the R33 phase. The project period for the R61 phase may not exceed three years while the project period of the R33 phase may not exceed two years.

5. Polygenic Risk Score (PRS) Methods and Analysis for Populations of Diverse Ancestry – Study Sites (U01 Clinical Trial Not Allowed or U01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-HG-20-001](#)
[RFA-HG-20-002](#)

Type: U01
U01

Application Due Date: June 23, 2020. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The goal of the intended FOA is to establish Study Sites for PRS Methods and Analysis for Populations of Diverse Ancestry to collaboratively generate and refine PRS for populations of diverse ancestry by integrating existing datasets with genomic and phenotype data for a range of complex diseases and traits. Together with a Coordinating Center (described in a separate FOA), grantees funded under the intended FOA will form a Consortium with the primary objectives of: 1) leveraging genetic diversity to develop methods and improve the applicability of PRS to predict health and disease risk across diverse populations, and for a broad range of health and disease measures; and 2) optimizing the integration of large-scale, harmonized genomic and phenotype data to facilitate collaborative analysis, dissemination of PRS-related data, and development of related methods and resources.

Budget: The following NIH components intend to commit the following amounts in FY 2021: NHGRI intends to commit up to \$5M in total costs to fund 3-5 awards & NCI intends to commit \$1M in total costs to fund 1 award. Future year amounts per award will depend on annual appropriations but total costs are estimated to be \$1M in FY2022, \$1M in FY2023, \$1M in FY2024, and \$1M in FY2025 per award. The award period for this FOA is 5 years (FY2021-2025).

Research Development and Support Division (RDSD),
Faculty of Medicine and Health Sciences, Stellenbosch University
5th Floor, Teaching Block, Tygerberg Campus.
Enquiries: *Christa*
e: cdevries@sun.ac.za | t: +27 21 938 9838

Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)
Stellenbosch University
2038 Wilcocks Building, Ryneveld Street
Enquiries: *Lizel*
e: lizelk@sun.ac.za | t: +27 21 808 2105